Biocogniv Analysis: $6M Raised
What is Biocogniv?
Biocogniv develops AI-based predictive diagnostics to detect acute conditions early, enhancing patient outcomes in emergency care settings.
Employees
6
Founded
2019
Revenue
$2.6M
Business Model
Revenue generated through software sales and licensing to healthcare institutions.
Product Features & Capabilities
- AI-based predictive diagnostics, Sepsis aiMarker™ detects and predicts sepsis up to 72 hours in advance using routine laboratory panels.
How much Biocogniv raised
Seed - $6 million
March 16, 2022Lead Investor: Breyer Capital
Who are the founders of Biocogniv
AA
Artur Adib
Founder
Market Focus
Biocogniv primarily focuses on the healthcare industry, specifically in the field of predictive diagnostics using artificial intelligence to assist in recognizing acute medical conditions.
Investors
- Unpopular Ventures
- Inflect Health
- Y Combinator
- America's Seed Fund
- 1984 Ventures
- AltaIR Capital
- Breyer Capital
- Dudley Fund
- Hula
Competitors Overview
Biocogniv operates in the AI-based predictive diagnostics market, focusing on helping healthcare providers recognize acute conditions early. Its main competitors include:
- Digital Reasoning: Specializes in AI-based consumer behavior analysis, primarily for financial institutions. It has raise
See something that needs updating? Suggest edits to this profile.